eMC Medicine Guides  
The electronic Medicines Compendium (eMC) contains information about UK licensed medicines.
go to eMC homepage
Search for:  
  Advanced Search

Daiichi Sankyo UK Limited
Chiltern Place, Chalfont Park, Gerrards Cross, Buckinghamshire, SL9 0BG, UK
Telephone: +44 (0)1753 482 771
Medical Information Direct Line: +44 (0)1753 482 771
Medical Information e-mail: medinfo@daiichi-sankyo.co.uk
Customer Care direct line: +44 (0)1753 482 771
Medical Information Fax: +44 (0)1753 893 894
Out of Hours Telephone: +44 (0)1748 828 818

Before you contact this company: often several companies will market medicines with the same active ingredient. Please check that this is the correct company before contacting them. Why?
Summary of Product Characteristics last updated on the eMC: 18/10/2011
SPC OLMETEC Plus film-coated tablets

When a pharmaceutical company changes an SPC or PIL, a new version is published on the eMC. For each version, we show the dates it was published on the eMC and the reasons for change.

Updated on 18/10/2011 and displayed until Current
Reasons for adding or updating:
  • Change to section 4.2 - Posology and method of administration
  • Change to section 4.6 - Pregnancy and Lactation
  • Change to section 4.8 - Undesirable Effects
  • Change to section 6.1 - List of Excipients
Date of revision of text on the SPC:   12-May-2010
Legal Category:   POM
Black Triangle (CHM):   YES

Free-text change information supplied by the pharmaceutical company
Various changes to the notified sections following a renewal procedure. Please refer to document.
Updated on 06/01/2010 and displayed until 18/10/2011
Reasons for adding or updating:
  • Correction of spelling/typing errors
Date of revision of text on the SPC:   25-Oct-2009
Legal Category:   POM
Black Triangle (CHM):   YES

Free-text change information supplied by the pharmaceutical company
None provided
Updated on 14/12/2009 and displayed until 06/01/2010
Reasons for adding or updating:
  • Change to section 2 - Qualitative and quantitative composition
  • Change to section 4.2 - Posology and method of administration
  • Change to section 4.3 - Contraindications
  • Change to section 4.4 - Special warnings and precautions for Use
  • Change to section 4.6 - Pregnancy and Lactation
  • Change to section 4.8 - Undesirable Effects
  • Change to section 5.2 - Pharmacokinetic Properties
  • Change to section 10 date of revision of the text
Date of revision of text on the SPC:   25-Oct-2009
Legal Category:   POM
Black Triangle (CHM):   YES

Free-text change information supplied by the pharmaceutical company
Section 2 (Qualitative and Quantitative Composition): Information on lactose content added
Setion 4.2 (Posology and method of administration):  Revised information - hepatic impairment
Section 4.3 (Contraindications):  Deletion of 'lactation'
Section 4.4 (Special warnings and precautions for use):  Revised information - hepatic imairment; pregnancy
Section 4.6 (Pregnancy and lactation): Revised information in line with PhVWP wording
Section 4,8 (Undesirable effects): Updated in line with post-marketing data; revised format
Section 5.2 (Pharmacokinetic properties):  Statement on hepatic impairment revised
Section 10 (Date of revision of text):  Updated to 25 October 2009 
Updated on 14/11/2006 and displayed until 14/12/2009
Reasons for adding or updating:
  • Company name change or merger
Date of revision of text on the SPC:   08/2006
Legal Category:   POM
Black Triangle (CHM):   YES

Free-text change information supplied by the pharmaceutical company

Section 7 Marketing Authorisation Holder - Updated from Sankyo Pharma UK Ltd to Daiichi Sankyo UK Ltd; Change of Address
Updated on 07/11/2006 and displayed until 14/11/2006
Reasons for adding or updating:
  • Change to section 4.2 - Posology and method of administration
  • Change to section 4.4 - Special warnings and precautions for Use
  • Change to section 4.8 - Undesirable Effects
  • Change to section 5.2 - Pharmacokinetic Properties
  • Pending awaiting re-submission
Date of revision of text on the SPC:   08/2006
Legal Category:   POM
Black Triangle (CHM):   NO

Free-text change information supplied by the pharmaceutical company
Section 4.2  Dosage statement regarding the Elderly has been amended.  Renal impairment - additional cross-reference to Section 4.4.
 
Section 4.4  Addition of statement regarding lactose.
 
Section 4.8  Additional information on special populations:  'In elderly patients the frequency of hypotension is slightly increased from rare to uncommon.'
 
Section 5.2  Additional statement regarding the Elderly.
Updated on 26/09/2006 and displayed until 07/11/2006
Reasons for adding or updating:
  • Change to section 7 - Marketing Authorisation Holder
Date of revision of text on the SPC:   08/2006
Legal Category:   POM
Black Triangle (CHM):   YES

Free-text change information supplied by the pharmaceutical company
7.  Marketing Authorisation Holder has been changed from Sankyo Pharma UK Ltd to Daiichi Sankyo UK Ltd; new Company Address.
Updated on 06/06/2006 and displayed until 26/09/2006
Reasons for adding or updating:
  • Correction of spelling/typing errors
Updated on 26/04/2006 and displayed until 06/06/2006
Reasons for adding or updating:
  • New SPC for new product

Active Ingredients/Generics

 
  hydrochlorothiazide
  olmesartan medoxomil